However, durable responses to immune checkpoint blockade (ICB) in HCC remain restricted to a minority of patients, with existing biomarkers (e.g., PD-L1, TMB) demonstrating limited clinical utility for guiding precision therapy due to intratumoral heterogeneity, high detection costs, and inconsistent predictive performance (4–6). The gene discussed is CD274; the disease is hepatocellular carcinoma.